Evrysdi (risdiplam)

Starting Evrysdi (risdiplam) very early — just 12 days after his birth and before his symptoms appeared — was safe and helped a boy with spinal muscular atrophy (SMA) achieve key motor milestones, such…

Treatment with Spinraza (nusinersen) or Evrysdi (risdiplam) may help preserve upper limb motor function in children and young adults with spinal muscular atrophy (SMA) type 2, a natural history study in Spain shows. In the…

After five years of treatment with Evrysdi (risdiplam), people with spinal muscular atrophy (SMA) types 2 and 3 continue to see stabilization and improvement in measures of motor function. That’s according to new long-term data from the…

Evrysdi (risdiplam) effectively improved motor function in adults with spinal muscular atrophy (SMA) type 2 or type 3, particularly skills like hand strength and function, a small study in France shows. Most patients…

Newborns diagnosed with spinal muscular atrophy (SMA) who were treated with Evrysdi (risdiplam) before the onset of symptoms are continuing to reach developmental milestones such as sitting, standing, and walking independently, with many achieving them in…

Spinal muscular atrophy (SMA) patients in the U.S. exhibited high rates of adherence to their prescribed regimen of Evrysdi (risdiplam) over a year, according to a recent analysis of pharmacy prescription fill data. “High adherence to and persistence with [Evrysdi] were observed among patients with SMA over…

Measuring the electrical activity of a pair of nerves that control arm movement, called the median nerves, could help assess how people with spinal muscular atrophy (SMA) respond to Evrysdi (risdiplam). That’s according to “Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic…